An open-label, dose escalation study in Japanese participants with relapsed/refractory multiple myeloma who have failed prior anti myeloma treatments

Trial Identifier: 207504
Sponsor: GlaxoSmithKline
Collaborator:
Not applicable
Start Date: March 2019
Primary Completion Date: April 2023
Study Completion Date: September 2024
Condition: Myeloma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Japan Aichi, Japan, 467-8602
Japan Okayama, Japan, 701-1192
Japan Tokyo, Japan, 135-8550
Japan, Tokyo Shibuya-Ku, Tokyo, Japan, 150-8935